We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

19 hedge funds and large institutions have $49.2M invested in Akari Therapeutics in 2015 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

46% more funds holding

Funds holding: 13 → 19 (+6)

23% less capital invested

Capital invested by funds: $63.5M → $49.2M (-$14.3M)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
19
Holders Change
+6
Holders Change %
+46.15%
% of All Funds
0.5%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
7
Increased
2
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
QF
QVT Financial
New York
+$4.9M
2
NMC
NEA Management Company
Maryland
+$1.75M
3
GTC
Ghost Tree Capital
New York
+$505K
4
Deutsche Bank
Deutsche Bank
Germany
+$371K
5
ACP
Acuta Capital Partners
California
+$312K

Top Sellers

Rank Fund Capital Flow
1
VM
VHCP Management
New York
-$6.86M
2
CAM
Cormorant Asset Management
Massachusetts
-$687K
3
DCM
DAFNA Capital Management
California
-$342K
4
Millennium Management
Millennium Management
New York
-$193K
5
TI
Turner Investments
Pennsylvania
-$178K
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$16.7M – – –
BBA
2
Baker Bros. Advisors
New York
$5.74M – – –
VMI
3
VHCP Management II
New York
$5.36M +$6.86M +462 New
RCM
4
RA Capital Management
Massachusetts
$3.83M – – –
FCMI
5
Foresite Capital Management III
California
$3.83M +$4.9M +330 New
QF
6
QVT Financial
New York
$3.64M +$4.9M +330 New
VM
7
VHCP Management
New York
$2.3M -$6.86M -462 -70%
BC
8
Boxer Capital
California
$2.03M +$2.6M +175 New
NMC
9
NEA Management Company
Maryland
$1.77M +$1.75M +118 +347%
EC
10
EcoR1 Capital
California
$1.46M – – –
Millennium Management
11
Millennium Management
New York
$743K -$193K -13 -17%
GTC
12
Ghost Tree Capital
New York
$683K +$505K +34 +136%
TI
13
Turner Investments
Pennsylvania
$468K -$178K -12 -23%
Deutsche Bank
14
Deutsche Bank
Germany
$286K +$371K +25 New
ACP
15
Acuta Capital Partners
California
$247K +$312K +21 New
DCM
16
DAFNA Capital Management
California
$121K -$342K -23 -70%
Bank of America
17
Bank of America
North Carolina
$22K +$29.7K +2 New
UBS Group
18
UBS Group
Switzerland
$10K – – –
TRCT
19
Tower Research Capital (TRC)
New York
$7K – – –
CAM
20
Cormorant Asset Management
Massachusetts
– -$687K -36 Closed

AKTX Hedge Fund Activity: Q4 2015 in Review

19 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q4 2015, worth a combined $49.2M — down 23% from $63.5M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AKTX positions and 1 closed out — a net gain of 6 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was QVT Financial, opening a new position worth an estimated $4.9M. The largest seller was VHCP Management, cutting an estimated $6.86M.

  • 19 institutional investors held Akari Therapeutics (AKTX) as of Q4 2015, up from 13 in Q3 2015.
  • Funds reported $49.2M of Akari Therapeutics stock for Q4 2015, down 23% quarter-over-quarter.
  • 7 funds opened new Akari Therapeutics positions in Q4 2015 and 1 closed out, a net change of +6 holders.
  • The largest Akari Therapeutics buyer in Q4 2015 was QVT Financial, an estimated $4.9M added.
  • The largest Akari Therapeutics seller in Q4 2015 was VHCP Management, an estimated $6.86M sold.

Based on aggregated 13F filings for Q4 2015.